
**TITLE: INTRAVENOUS TO ORAL CONVERSION FOR
 ANTIMICROBIALS**

A printed copy of this document may not reflect the current, electronic version on OurNH.

APPLICABILITY: All sites and facilities

**RELATED
POLICIES:** 1-20-6-4-090: [Medication Adaptation](#)

DEFINITIONS: **Antimicrobial:** An antibiotic, antifungal or antiviral; **Bioavailability:**
amount of drug absorbed into the body; **Potency:** combination of
bioavailability plus amount of actual body exposure to drug after
administration of 1 dose (area under the curve = AUC)

**COMPETENCY
REQUIREMENTS:**

KEY POINTS

- Timely conversion from intravenous (IV) to oral (PO) antimicrobial therapy is effective for a variety of infections, especially for agents with excellent bioavailability.
- Conversion from IV to PO antimicrobials in select patients results in cost savings for the facility as well as aim for positive clinical outcomes such as shortened hospital stay, reduced risk of line-related infections and adverse events and no IV related mobility restrictions for patients.

POLICY STATEMENT (ALL STAFF MUST COMPLY)

All patients initiated on IV antimicrobials will be assessed for conversion to oral antibiotics. Oral antimicrobials will be used preferentially whenever appropriate for the clinical circumstances of the patient.

**CLINICAL PRACTICE STANDARD (ALWAYS USE PROFESSIONAL JUDGMENT AND
DOCUMENT ANY DEVIATION FROM THE STANDARD)**

Consider a change in route of administration of antimicrobial drug therapy when the following circumstances apply:

1. Improving clinically
 - Consistent improvement in fever over the last 24 hours or patient is afebrile (less than 38°C), and
 - White blood cells decreasing, and

- Hemodynamically stable
2. Able to tolerate and absorb oral medications
 - Tolerating enteral feeds or eating/drinking fluid diet; taking other medications orally
 - No severe or persistent nausea, vomiting or diarrhea
 - No gastrointestinal obstruction, ileus, malabsorption syndrome, active gastrointestinal (GI) bleed or continuous gastric suctioning if orogastric/nasogastric (N/G).
 3. Pathogen is not known to be resistant to the oral antimicrobial to be used
 4. Patient **does not** have any of the following **exclusion** criteria:
 - Patient is less than or equal to 18 years of age (paediatric patients)
 - Nothing by mouth (NPO) status with no medications being given orally
 - Continuous feeds that cannot be held if antimicrobial agent known to bind to enteral nutrition formulation
 - Difficulty swallowing or loss of consciousness and no orogastric/N/G available
 - Short Gut syndrome
 - Acute treatment phase of listed conditions (discuss with infectious disease physician involved)
 - Febrile neutropenia
 - Bacteremia with *staphylococcus aureus* or Enterococcus species
 - Severe sepsis
 - CNS infection (e.g., meningitis, encephalitis)
 - Endophthalmitis
 - Endocarditis
 - Osteomyelitis/discitis
 - Vertebral or deep abscesses
 - Bone and joint infections
 - Septic arthritis

IV to PO Conversion Regimen Recommendations

Oral antimicrobials equally potent to the IV formulation		
Parenteral Therapy	Oral Therapy	Oral Bioavailability
Ciprofloxacin 200 mg IV q12h Ciprofloxacin 400 mg IV q12h	Ciprofloxacin 250 mg PO BID Ciprofloxacin 500 to 750 mg PO BID NOTE: space oral dose two hours before or six hours after calcium, magnesium and iron. Hold enteral feeds one hour before and after dose (do not use oral suspension in feeding tubes due to clogging)	70%
Clindamycin 600 mg IV q8h	Clindamycin 450 mg PO TID	90%
Fluconazole IV once daily (daily dose same for both IV and PO administration)	Fluconazole po once daily (daily dose same for both IV and PO administration)	90%
Metronidazole 500 mg IV q8h Metronidazole 500 mg IV q12h	Metronidazole 500 mg PO TID Metronidazole 500 mg PO BID	100%
Moxifloxacin 400 mg IV once daily	Moxifloxacin 400 mg PO once daily	90%
Sulfamethoxazole –trimethoprim (co-trimoxazole) 800/160 mg IV q8h	Sulfamethoxazole –trimethoprim (co-trimoxazole) 1 DS tab PO BID	85%
Voriconazole 400 mg IV q12h x 2 doses then 200 mg IV q12h	Voriconazole 400 mg PO BID x 2 doses then 200 mg PO BID	96%

NOTE: Adjust the above doses for the indication, patient's age, weight, and renal function when necessary.

Oral antimicrobials less potent than IV formulation. Step-down to a less potent oral agent requires individual patient assessment		
Parenteral Therapy	Oral Therapy***	Oral Bioavailability
Azithromycin 500 mg IV once daily	Azithromycin 250 mg PO once daily	37%*
Cefazolin 1 g IV q8h	Cephalexin*** 500 mg PO QID	90%
Cefuroxime 750 mg IV q8h Cefuroxime 1.5 g IV q8h	Cefuroxime 500 mg PO BID with food	50%
Cloxacillin 1_to 2 g IV q6h	Cloxacillin 500 mg PO QID one hour before or two hours after meals or Cephalexin 500mg po QID	50%
Penicillin G 1_to 2 million units IV q6h	Penicillin V 300 mg PO QID or Amoxicillin 500 mg PO TID	60-73% Amoxi = 80%
Acyclovir# 5mg/kg IV q8h	Acyclovir# 400 mg PO TID or Valacyclovir# 1 g po BID	Acyclovir = 10 – 20% Valacyclovir = 54%

NOTE: The above doses should be adjusted for the indication, patient's age, weight, and renal function when necessary.

*low bioavailability but rapidly moves into tissues resulting in low serum concentrations but high and persistent tissue concentrations (note 500mg oral dose = loading dose)

*** If a pathogen has been identified ensure the organism is susceptible. Note: cephalothin is the representing agent in microbiology testing for cephalixin

Doses vary depending on indication

Intravenous antimicrobials without oral formulations		
Parenteral Therapy	Oral Therapy***	Oral Bioavailability
Ampicillin 500 mg IV q8h Ampicillin 1 g IV q6h	Amoxicillin 500mg PO TID	80%
Ceftazidime 2 g IV q8h	Ciprofloxacin 750 mg PO BID (for Pseudomonas species)	70%
Ceftriaxone 1 to2 g IV q24h	Ciprofloxacin 500 to 750 mg PO BID +/- Cephalixin 500 mg PO QID	Cipro = 70% Cephalixin = 90%
Gentamicin 6 mg/kg ideal body weight** IV q24h or Tobramycin 6 mg/kg ideal body weight** IV q24h	Ciprofloxacin 750 mg PO BID (for Pseudomonas species)	Cipro = 70%
Piperacillin/Tazobactam 3.375 g IV q6hr	Amoxicillin/clavulanate 500/125mg PO TID or Ciprofloxacin 500 to 750 mg PO BID + Metronidazole 500 mg PO BID or Ciprofloxacin 500 to 750 mg PO BID + Clindamycin 450 mg PO TID	Amoxicillin= 80% clavulanate = 30 -98% Cipro = 70% Metro = 100% Clinda = 90%

NOTE: The above doses should be adjusted for the indication, patient's age, weight, and renal function when necessary.

** Contact pharmacy for dosing

*** If a pathogen has been identified ensure the organism is susceptible. Note: cephalothin is the representing agent in microbiology testing for cephalixin

DOCUMENTATION

Document recommendations to the most responsible physician for oral antimicrobial conversion in the physician progress notes section of patient's chart.

Document accepted recommendations as a medication order in the physician's order section of the patient's chart.

KEYWORDS

Antimicrobials, antimicrobial stewardship, antimicrobial conversion, IV to PO step-down. OG, ng, og, NG

REFERENCES

- Vancouver Coastal Health. (2007, June). Prescribing policies. 4.6 Pharmacist managed IV - PO conversion program. Retrieved on October 23, 2014 from <http://www.vhpharmsci.com/VHFormulary/Policies/4.6%20IV-PO%20STEPDOWN%20PROGRAM.pdf>
- Interior Health Authority. (2015, January). Clinical Practice Standard and Procedure. Pharmacist managed intravenous to oral sequential antimicrobial therapy in adults.
- Ottawa Hospital P&T Committee and MAC. (2013, October). Pharmacist initiated intravenous to oral automatic substitution for antimicrobial agents. Version 2.
- Markham Stouffville Hospital. (2012, April). Interdisciplinary Manual. Medication Guidelines & protocols. Pharmacist –initiated IV to PO conversion program of antimicrobials. 290.914.916.010.
- Sun Country Health Region. (2014, September). Integrated and Primary Care. Step-down protocols for Antimicrobials. IPC -55-15-20.